Table 1 Patient characteristics, medications and type of surgery in all patients, and comparing those with and without left ventricular diastolic dysfunction established by comprehensive assessment

Number of patients

96

22

74

Age (years)

63 ± 12

51 ± 13

67 ± 9

< 0.001

Body mass index (kg m⁻²)

27 ± 4

25 ± 3

27 ± 4

0.041

Female sex, n (%)

84 (88)

17 (77)

68 (92)

0.017

Smoker, n (%)

21 (22)

1 (5)

20 (27)

0.025

MET < 4

25 (26)

2 (9)

23 (31)

0.039

ASA-PS III

28 (29)

1 (5)

27 (36)

0.004

NYHA (0)

60 (63)

22 (100)

0 (0)

< 0.001*

NYHA (I)

8 (8.3)

0 (0)

8 (11)

0.192*

NYHA (II)

6 (6)

0 (0)

6 (8)

0.331*

NYHA (III)

22 (23)

0 (0)

22 (30)

0.003*

NT-proBNP (ng L^− 1)

90 [197]

65 [69]

128 [299]

0.001*

hs-TnI (ng L^− 1)

6.8 ± 5.2

4.9 ± 2.4

7.4 ± 5.6

0.004

Haemoglobin (g L^L1)

134 ± 15

139 ± 15

132 ± 14

0.081

Creatinine (μmol L⁻¹)

87 ± 93

68 ± 16

92 ± 103

0.316

eGFR (mL/min/L.73m²)

70 ± 19

82 ± 10

67 ± 20

0.003

Co-morbidities

 Hypertension

67 (70)

11 (50)

57 (77)

0.014

 Renal failure

21 (23)

0 (0)

21 (28)

< 0.001

 Angina pectoris

14 (15)

0 (0)

14 (19)

0.027

 Bronchial asthma

17 (18)

0 (0)

17 (23)

0.013

 COPD

12 (13)

1 (5)

11 (15)

0.199

 Diabetes mellitus

9 (9)

2 (9)

7 (9)

0.958

 Beta-blockers

33 (34)

2 (9)

31 (42)

0.004

 Calcium channel blockers

24 (25)

3 (14)

21 (28)

0.161

 ACE- inhibitors

17 (18)

2 (9)

15 (20)

0.228

 Angiotensin receptor blockers

20 (21)

2 (9)

18 (24)

0.122

 Diuretics

26 (27)

0 (0)

26 (35)

0.001

 Nitroglycerine

9 (9)

0 (0)

9 (12)

0.086

Combination therapy*

36 (38)

2 (9)

34 (46)

0.002

 Breast

65 (68)

16 (73)

49 (66)

0.566

 Thyroid

16 (17)

3 (14)

13 (18)

0.664

 Minor GI

15 (16)

3 (14)

12 (16)

0.770